Latigo Biotherapeutics, Inc. Common Stock (LTGO) Stock
Key stats
- Market cap
- $896.37M
- Price / Earnings ratio
- -8.1x
- EPS (TTM)
- -$129.23
- Volume
- Loading
- 52-week high
- $25.93
- 52-week low
- $10.24
Source: third-party data provider, as of November 13, 2026
Compare with LTGO
Recent news

Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public
Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public
LTGO

Latigo, BlossomHill launch US IPOs as biotech listings rebound
Latigo, BlossomHill launch US IPOs as biotech listings rebound
LTGO

Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain
Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain
LTGO
Technical indicators
- RSI 14
- 41.09
- MACD 12/26/9
- -1.04
- EMA 9 of MACD
- -1.05
- MACD histogram
- 0.02
- SMA 50
- $17.39
- Price below SMA 50
- EMA 50
- $16.98
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public
Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public
LTGO

Latigo, BlossomHill launch US IPOs as biotech listings rebound
Latigo, BlossomHill launch US IPOs as biotech listings rebound
LTGO

Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain
Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain
LTGO
About Latigo Biotherapeutics, Inc. Common Stock
Latigo Bio is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Nima Farzan M.B.A. | CEO, President & Director | 1976 |
| Ms. Neha Krishnamohan | Chief Business Officer & CFO | 1987 |
| Dr. Neil Kumar Singla M.D. | Chief Medical Officer | 1972 |
| Ms. Julia Chapman | Senior Vice President of Operations | — |
| Ms. Caroline Dougherty | Vice President of Corporate Development | — |
| Mr. Bryan Moyer Ph.D. | Senior Vice President of Discovery | — |
| Ms. Polina German Pharm.D. | Senior Vice President of Clinical Pharmacology & Translational | — |
| Ms. Sabrina Nieder | VP & Corporate Controller | — |
| Vicki Holloway | Secretary | — |
Fundamentals
Valuation
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 41.09
- MACD 12/26/9
- -1.04
- EMA 9 of MACD
- -1.05
- MACD histogram
- 0.02
- SMA 50
- $17.39
- Price below SMA 50
- EMA 50
- $16.98
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $36.00
- Average
- $45.33
- High
- $50.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +20.7 | -25.0 | -16.4 | +0.1 |



